Solid Biosciences stockholders approve reverse stock split and authorized share increase

Solid Biosciences Inc.

Elected Class I directors Huffines, Nagendran, Shah with ~65.9M votes each.
Ratified PricewaterhouseCoopers as auditor for FY2022: 87.3M for, 226.9K against.
Approved reverse stock split at ratio of 1:5 to 1:15, board to set exact ratio before 2023 annual meeting.
Approved increase in authorized shares to 300M multiplied by 3x the reverse split ratio.
Reverse split and share increase subject to board discretion; may be abandoned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.